Exact Mass: 658.3928

Exact Mass Matches: 658.3928

Found 243 metabolites which its exact mass value is equals to given mass value 658.3928, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Fucoxanthin

(3S,3′S,5R,5′R,6S,6′R)-3′-(Acetyloxy)-6′,7′-didehydro-5,6-epoxy-5,5′,6,6′,7,8-hexahydro-3,5′-dihydroxy-8-oxo-β,β-carotene

C42H58O6 (658.4233)


Fucoxanthin is an epoxycarotenol that is found in brown seaweed and which exhibits anti-cancer, anti-diabetic, anti-oxidative and neuroprotective properties. It has a role as an algal metabolite, a CFTR potentiator, a food antioxidant, a neuroprotective agent, a hypoglycemic agent, an apoptosis inhibitor, a hepatoprotective agent, a marine metabolite and a plant metabolite. It is an epoxycarotenol, an acetate ester, a secondary alcohol, a tertiary alcohol and a member of allenes. Fucoxanthin is a natural product found in Aequipecten opercularis, Ascidia zara, and other organisms with data available. Fucoxanthin is a carotenoid, with formula C40H60O6. It is found as an accessory pigment in the chloroplasts of brown algae and most other heterokonts, giving them a brown or olive-green color. Fucoxanthin absorbs light primarily in the blue-green to yellow-green part of the visible spectrum, peaking at around 510-525 nm by various estimates and absorbing significantly in the range of 450 to 540 nm. -- Wikipedia [HMDB] Fucoxanthin is a carotenoid, with formula C40H60O6. It is found as an accessory pigment in the chloroplasts of brown algae and most other heterokonts, giving them a brown or olive-green color. Fucoxanthin absorbs light primarily in the blue-green to yellow-green part of the visible spectrum, peaking at around 510-525 nm by various estimates and absorbing significantly in the range of 450 to 540 nm. -- Wikipedia. D020011 - Protective Agents > D000975 - Antioxidants > D002338 - Carotenoids Fucoxanthin (all-trans-Fucoxanthin) is a marine carotenoid and shows anti-obesity, anti-diabetic, anti-oxidant, anti-inflammatory and anticancer activities[1][2][3][4][5][6][7][8][9]. Fucoxanthin is a marine carotenoid and shows anti-obesity, anti-diabetic, anti-oxidant, anti-inflammatory and anticancer activities. Fucoxanthin (all-trans-Fucoxanthin) is a marine carotenoid and shows anti-obesity, anti-diabetic, anti-oxidant, anti-inflammatory and anticancer activities[1][2][3][4][5][6][7][8][9]. Fucoxanthin. CAS Common Chemistry. CAS, a division of the American Chemical Society, n.d. https://commonchemistry.cas.org/detail?cas_rn=3351-86-8 (retrieved 2024-11-06) (CAS RN: 3351-86-8). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0).

   

PA(10:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

[(2R)-3-(decanoyloxy)-2-{[(5R,6R,7Z,9Z,11E,13E,15S,17Z)-5,6,15-trihydroxyicosa-7,9,11,13,17-pentaenoyl]oxy}propoxy]phosphonic acid

C33H55O11P (658.3482)


PA(10:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of Lipoxin A5 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5S,6S,7Z,9Z,11E,13E,15R,17Z)-5,6,15-trihydroxyicosa-7,9,11,13,17-pentaenoyl]oxy}propoxy]phosphonic acid

C33H55O11P (658.3482)


PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/10:0), in particular, consists of one chain of one Lipoxin A5 at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(12:0/20:3(6,8,11)-OH(5))

[(2R)-3-(dodecanoyloxy)-2-{[(6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoyl]oxy}propoxy]phosphonic acid

C35H63O9P (658.4209)


PA(12:0/20:3(6,8,11)-OH(5)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/20:3(6,8,11)-OH(5)), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of 5-hydroxyeicosatetrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(6,8,11)-OH(5)/12:0)

[(2R)-2-(dodecanoyloxy)-3-{[(6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoyl]oxy}propoxy]phosphonic acid

C35H63O9P (658.4209)


PA(20:3(6,8,11)-OH(5)/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(6,8,11)-OH(5)/12:0), in particular, consists of one chain of one 5-hydroxyeicosatetrienoyl at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:0/18:2(10E,12Z)+=O(9))

[(2R)-2-{[(10E,12Z)-9-oxooctadeca-10,12-dienoyl]oxy}-3-(tetradecanoyloxy)propoxy]phosphonic acid

C35H63O9P (658.4209)


PA(14:0/18:2(10E,12Z)+=O(9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:0/18:2(10E,12Z)+=O(9)), in particular, consists of one chain of one tetradecanoyl at the C-1 position and one chain of 9-oxo-octadecadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:2(10E,12Z)+=O(9)/14:0)

[(2R)-3-{[(10E,12Z)-9-oxooctadeca-10,12-dienoyl]oxy}-2-(tetradecanoyloxy)propoxy]phosphonic acid

C35H63O9P (658.4209)


PA(18:2(10E,12Z)+=O(9)/14:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:2(10E,12Z)+=O(9)/14:0), in particular, consists of one chain of one 9-oxo-octadecadienoyl at the C-1 position and one chain of tetradecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:0/18:2(9Z,11E)+=O(13))

[(2R)-2-{[(9Z,11E)-13-oxooctadeca-9,11-dienoyl]oxy}-3-(tetradecanoyloxy)propoxy]phosphonic acid

C35H63O9P (658.4209)


PA(14:0/18:2(9Z,11E)+=O(13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:0/18:2(9Z,11E)+=O(13)), in particular, consists of one chain of one tetradecanoyl at the C-1 position and one chain of 13-oxo-octadecadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:2(9Z,11E)+=O(13)/14:0)

[(2R)-3-{[(9Z,11E)-13-oxooctadeca-9,11-dienoyl]oxy}-2-(tetradecanoyloxy)propoxy]phosphonic acid

C35H63O9P (658.4209)


PA(18:2(9Z,11E)+=O(13)/14:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:2(9Z,11E)+=O(13)/14:0), in particular, consists of one chain of one 13-oxo-octadecadienoyl at the C-1 position and one chain of tetradecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:0/18:3(10,12,15)-OH(9))

[(2R)-2-{[(10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoyl]oxy}-3-(tetradecanoyloxy)propoxy]phosphonic acid

C35H63O9P (658.4209)


PA(14:0/18:3(10,12,15)-OH(9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:0/18:3(10,12,15)-OH(9)), in particular, consists of one chain of one tetradecanoyl at the C-1 position and one chain of 9-hydroxyoctadecatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:3(10,12,15)-OH(9)/14:0)

[(2R)-3-{[(10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoyl]oxy}-2-(tetradecanoyloxy)propoxy]phosphonic acid

C35H63O9P (658.4209)


PA(18:3(10,12,15)-OH(9)/14:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:3(10,12,15)-OH(9)/14:0), in particular, consists of one chain of one 9-hydroxyoctadecatrienoyl at the C-1 position and one chain of tetradecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:0/18:3(9,11,15)-OH(13))

[(2R)-2-{[(9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoyl]oxy}-3-(tetradecanoyloxy)propoxy]phosphonic acid

C35H63O9P (658.4209)


PA(14:0/18:3(9,11,15)-OH(13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:0/18:3(9,11,15)-OH(13)), in particular, consists of one chain of one tetradecanoyl at the C-1 position and one chain of 13-hydroxyoctadecatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:3(9,11,15)-OH(13)/14:0)

[(2R)-3-{[(9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoyl]oxy}-2-(tetradecanoyloxy)propoxy]phosphonic acid

C35H63O9P (658.4209)


PA(18:3(9,11,15)-OH(13)/14:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:3(9,11,15)-OH(13)/14:0), in particular, consists of one chain of one 13-hydroxyoctadecatrienoyl at the C-1 position and one chain of tetradecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:1(9Z)/18:1(12Z)-O(9S,10R))

[(2R)-2-[(8-{3-[(2Z)-oct-2-en-1-yl]oxiran-2-yl}octanoyl)oxy]-3-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C35H63O9P (658.4209)


PA(14:1(9Z)/18:1(12Z)-O(9S,10R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:1(9Z)/18:1(12Z)-O(9S,10R)), in particular, consists of one chain of one 9Z-tetradecenoyl at the C-1 position and one chain of 9,10-epoxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:1(12Z)-O(9S,10R)/14:1(9Z))

[(2R)-3-[(8-{3-[(2Z)-oct-2-en-1-yl]oxiran-2-yl}octanoyl)oxy]-2-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C35H63O9P (658.4209)


PA(18:1(12Z)-O(9S,10R)/14:1(9Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:1(12Z)-O(9S,10R)/14:1(9Z)), in particular, consists of one chain of one 9,10-epoxy-octadecenoyl at the C-1 position and one chain of 9Z-tetradecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:1(9Z)/18:1(9Z)-O(12,13))

[(2R)-2-{[(9Z)-11-(3-pentyloxiran-2-yl)undec-9-enoyl]oxy}-3-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C35H63O9P (658.4209)


PA(14:1(9Z)/18:1(9Z)-O(12,13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:1(9Z)/18:1(9Z)-O(12,13)), in particular, consists of one chain of one 9Z-tetradecenoyl at the C-1 position and one chain of 12,13-epoxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:1(9Z)-O(12,13)/14:1(9Z))

[(2R)-3-{[(9Z)-11-(3-pentyloxiran-2-yl)undec-9-enoyl]oxy}-2-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C35H63O9P (658.4209)


PA(18:1(9Z)-O(12,13)/14:1(9Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:1(9Z)-O(12,13)/14:1(9Z)), in particular, consists of one chain of one 12,13-epoxy-octadecenoyl at the C-1 position and one chain of 9Z-tetradecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-12:0/20:3(6,8,11)-OH(5))

[(2R)-2-{[(6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoyl]oxy}-3-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H63O9P (658.4209)


PA(i-12:0/20:3(6,8,11)-OH(5)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/20:3(6,8,11)-OH(5)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 5-hydroxyeicosatetrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(6,8,11)-OH(5)/i-12:0)

[(2R)-3-{[(6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoyl]oxy}-2-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H63O9P (658.4209)


PA(20:3(6,8,11)-OH(5)/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(6,8,11)-OH(5)/i-12:0), in particular, consists of one chain of one 5-hydroxyeicosatetrienoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-14:0/18:2(10E,12Z)+=O(9))

[(2R)-3-[(12-methyltridecanoyl)oxy]-2-{[(10E,12Z)-9-oxooctadeca-10,12-dienoyl]oxy}propoxy]phosphonic acid

C35H63O9P (658.4209)


PA(i-14:0/18:2(10E,12Z)+=O(9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-14:0/18:2(10E,12Z)+=O(9)), in particular, consists of one chain of one 12-methyltridecanoyl at the C-1 position and one chain of 9-oxo-octadecadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:2(10E,12Z)+=O(9)/i-14:0)

[(2R)-2-[(12-methyltridecanoyl)oxy]-3-{[(10E,12Z)-9-oxooctadeca-10,12-dienoyl]oxy}propoxy]phosphonic acid

C35H63O9P (658.4209)


PA(18:2(10E,12Z)+=O(9)/i-14:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:2(10E,12Z)+=O(9)/i-14:0), in particular, consists of one chain of one 9-oxo-octadecadienoyl at the C-1 position and one chain of 12-methyltridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-14:0/18:2(9Z,11E)+=O(13))

[(2R)-3-[(12-methyltridecanoyl)oxy]-2-{[(9Z,11E)-13-oxooctadeca-9,11-dienoyl]oxy}propoxy]phosphonic acid

C35H63O9P (658.4209)


PA(i-14:0/18:2(9Z,11E)+=O(13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-14:0/18:2(9Z,11E)+=O(13)), in particular, consists of one chain of one 12-methyltridecanoyl at the C-1 position and one chain of 13-oxo-octadecadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:2(9Z,11E)+=O(13)/i-14:0)

[(2R)-2-[(12-methyltridecanoyl)oxy]-3-{[(9Z,11E)-13-oxooctadeca-9,11-dienoyl]oxy}propoxy]phosphonic acid

C35H63O9P (658.4209)


PA(18:2(9Z,11E)+=O(13)/i-14:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:2(9Z,11E)+=O(13)/i-14:0), in particular, consists of one chain of one 13-oxo-octadecadienoyl at the C-1 position and one chain of 12-methyltridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-14:0/18:3(10,12,15)-OH(9))

[(2R)-2-{[(10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoyl]oxy}-3-[(12-methyltridecanoyl)oxy]propoxy]phosphonic acid

C35H63O9P (658.4209)


PA(i-14:0/18:3(10,12,15)-OH(9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-14:0/18:3(10,12,15)-OH(9)), in particular, consists of one chain of one 12-methyltridecanoyl at the C-1 position and one chain of 9-hydroxyoctadecatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:3(10,12,15)-OH(9)/i-14:0)

[(2R)-3-{[(10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoyl]oxy}-2-[(12-methyltridecanoyl)oxy]propoxy]phosphonic acid

C35H63O9P (658.4209)


PA(18:3(10,12,15)-OH(9)/i-14:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:3(10,12,15)-OH(9)/i-14:0), in particular, consists of one chain of one 9-hydroxyoctadecatrienoyl at the C-1 position and one chain of 12-methyltridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-14:0/18:3(9,11,15)-OH(13))

[(2R)-2-{[(9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoyl]oxy}-3-[(12-methyltridecanoyl)oxy]propoxy]phosphonic acid

C35H63O9P (658.4209)


PA(i-14:0/18:3(9,11,15)-OH(13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-14:0/18:3(9,11,15)-OH(13)), in particular, consists of one chain of one 12-methyltridecanoyl at the C-1 position and one chain of 13-hydroxyoctadecatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:3(9,11,15)-OH(13)/i-14:0)

[(2R)-3-{[(9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoyl]oxy}-2-[(12-methyltridecanoyl)oxy]propoxy]phosphonic acid

C35H63O9P (658.4209)


PA(18:3(9,11,15)-OH(13)/i-14:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:3(9,11,15)-OH(13)/i-14:0), in particular, consists of one chain of one 13-hydroxyoctadecatrienoyl at the C-1 position and one chain of 12-methyltridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

Bugbanoside E

Bugbanoside E

C37H54O10 (658.3717)


   

Acutissimatriterpene C

Acutissimatriterpene C

C40H50O8 (658.3506)


   
   

Incarvillateine C

Incarvillateine C

C40H54N2O6 (658.3982)


   
   

Sileneoside C

Sileneoside C

C33H54O13 (658.3564)


   
   

3alpha,15alpha,22-triacetoxy-7alpha-ethoxy-5alpha-lanost-8,24E-dien-26-oic acid|7-O-ethyl ganoderic acid O

3alpha,15alpha,22-triacetoxy-7alpha-ethoxy-5alpha-lanost-8,24E-dien-26-oic acid|7-O-ethyl ganoderic acid O

C38H58O9 (658.4081)


   

26-Deoxycimicifugoside

26-Deoxycimicifugoside

C37H54O10 (658.3717)


   

Grandidone C

Grandidone C

C40H50O8 (658.3506)


   

5-alpha-Hydroxyecdysone 3-beta-D-glucoside

5-alpha-Hydroxyecdysone 3-beta-D-glucoside

C33H54O13 (658.3564)


   

certonardoside J2

certonardoside J2

C35H62O11 (658.4292)


   

gamabufotalin 3-succinoylarginine ester|Gamabufotalin-3-succinoylargininester

gamabufotalin 3-succinoylarginine ester|Gamabufotalin-3-succinoylargininester

C34H50N4O9 (658.3578)


   

CARATUBERSIDE B

CARATUBERSIDE B

C34H58O12 (658.3928)


   

Isophytolaccagenin A

Isophytolaccagenin A

C37H54O10 (658.3717)


   

20-Hydroxyecdysone 3-O-??-D-glucoside

20-Hydroxyecdysone 3-O-??-D-glucoside

C33H54O13 (658.3564)


   

12-O-hexadecanoyl-7-oxo-5-ene-phorbol-13-acetate

12-O-hexadecanoyl-7-oxo-5-ene-phorbol-13-acetate

C38H58O9 (658.4081)


   

Isofucoxanthin

Isofucoxanthin

C42H58O6 (658.4233)


   

3-O-beta-D-glucopyranosyl-(3beta,16alpha,20S)-pregn-5-ene-3,16,20-triol 20-O-beta-D-glucopyranoside|periseoside E

3-O-beta-D-glucopyranosyl-(3beta,16alpha,20S)-pregn-5-ene-3,16,20-triol 20-O-beta-D-glucopyranoside|periseoside E

C33H54O13 (658.3564)


   

bastaxanthol dimethyl ketal

bastaxanthol dimethyl ketal

C42H58O6 (658.4233)


   

Milbemycin alpha-7

Milbemycin alpha-7

C37H54O10 (658.3717)


   

floralginsenoside Tb

floralginsenoside Tb

C35H62O11 (658.4292)


   

tolocinobufagin-3-succinoylarginine ester

tolocinobufagin-3-succinoylarginine ester

C34H50N4O9 (658.3578)


   

3-O-acetylcimicifugoside H-1

3-O-acetylcimicifugoside H-1

C37H54O10 (658.3717)


   

cercosporene E

cercosporene E

C40H50O8 (658.3506)


   

leptasteroside L

leptasteroside L

C35H62O11 (658.4292)


   

Antibiotic X 14873A

Antibiotic X 14873A

C35H62O11 (658.4292)


   

triacetate methylester de lacide zanhique-delta-lactone

triacetate methylester de lacide zanhique-delta-lactone

C37H54O10 (658.3717)


   

(3beta,17alpha,20S)-pregn-5-ene-3,17,20-triol 3-O-beta-D-glucopyranosyl-(1->6)-beta-D-glucopyranoside|periseoside B

(3beta,17alpha,20S)-pregn-5-ene-3,17,20-triol 3-O-beta-D-glucopyranosyl-(1->6)-beta-D-glucopyranoside|periseoside B

C33H54O13 (658.3564)


   

all-trans-Fucoxanthin

all-trans-Fucoxanthin

C42H58O6 (658.4233)


   

3-O-beta-Gentiobiosyl-3beta,14-dihydroxy-5alpha,14beta-pregnan-20-one

3-O-beta-Gentiobiosyl-3beta,14-dihydroxy-5alpha,14beta-pregnan-20-one

C33H54O13 (658.3564)


   

eremodimer A

eremodimer A

C40H50O8 (658.3506)


   

23-Epi-26-deoxycimicifugoside

23-Epi-26-deoxycimicifugoside

C37H54O10 (658.3717)


   

9H7XN615A3

[(1R,1S,3R,4S,4R,5R,5R,6R,10S,12S,16R,18S,21R)-1,4,6,12,17,17-hexamethyl-18-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyspiro[3,6-dioxabicyclo[3.1.0]hexane-4,8-9-oxahexacyclo[11.9.0.01,21.04,12.05,10.016,21]docos-13-ene]-3-yl] acetate

C37H54O10 (658.3717)


26-Deoxycimicifugoside is a natural product found in Actaea asiatica, Actaea racemosa, and Actaea simplex with data available. See also: Black Cohosh (part of).

   

Fucoxanthin

InChI=1/C42H58O6/c1-29(18-14-19-31(3)22-23-37-38(6,7)26-35(47-33(5)43)27-40(37,10)46)16-12-13-17-30(2)20-15-21-32(4)36(45)28-42-39(8,9)24-34(44)25-41(42,11)48-42/h12-22,34-35,44,46H,24-28H2,1-11H3/b13-12+,18-14+,20-15+,29-16+,30-17+,31-19+,32-21+/t23?,34-

C42H58O6 (658.4233)


Fucoxanthin is an epoxycarotenol that is found in brown seaweed and which exhibits anti-cancer, anti-diabetic, anti-oxidative and neuroprotective properties. It has a role as an algal metabolite, a CFTR potentiator, a food antioxidant, a neuroprotective agent, a hypoglycemic agent, an apoptosis inhibitor, a hepatoprotective agent, a marine metabolite and a plant metabolite. It is an epoxycarotenol, an acetate ester, a secondary alcohol, a tertiary alcohol and a member of allenes. Fucoxanthin is a natural product found in Aequipecten opercularis, Ascidia zara, and other organisms with data available. An epoxycarotenol that is found in brown seaweed and which exhibits anti-cancer, anti-diabetic, anti-oxidative and neuroprotective properties. D020011 - Protective Agents > D000975 - Antioxidants > D002338 - Carotenoids Window width to select the precursor ion was 3 Da.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 19HP8024 to the Mass Spectrometry Society of Japan. Window width for selecting the precursor ion was 3 Da.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 16HP2005 to the Mass Spectrometry Society of Japan. Fucoxanthin (all-trans-Fucoxanthin) is a marine carotenoid and shows anti-obesity, anti-diabetic, anti-oxidant, anti-inflammatory and anticancer activities[1][2][3][4][5][6][7][8][9]. Fucoxanthin is a marine carotenoid and shows anti-obesity, anti-diabetic, anti-oxidant, anti-inflammatory and anticancer activities. Fucoxanthin (all-trans-Fucoxanthin) is a marine carotenoid and shows anti-obesity, anti-diabetic, anti-oxidant, anti-inflammatory and anticancer activities[1][2][3][4][5][6][7][8][9]. Fucoxanthin is a marine carotenoid and shows anti-obesity, anti-diabetic, anti-oxidant, anti-inflammatory and anticancer activities.

   

Fucoxanthin_major

Fucoxanthin_major

C42H58O6 (658.4233)


   

Fucoxanthin_57.0\\%

Fucoxanthin_57.0\\%

C42H58O6 (658.4233)


   

HLKYV

His-Leu-Lys-Tyr-Val

C32H50N8O7 (658.3802)


   

Bisoctrizole

Bisoctrizole

C41H50N6O2 (658.3995)


C1892 - Chemopreventive Agent > C851 - Sunscreen

   

zinc diricinoleate

zinc diricinoleate

C36H66O6Zn (658.4151)


   

PA(14:0/18:2(10E,12Z)+=O(9))

PA(14:0/18:2(10E,12Z)+=O(9))

C35H63O9P (658.4209)


   

PA(18:2(10E,12Z)+=O(9)/14:0)

PA(18:2(10E,12Z)+=O(9)/14:0)

C35H63O9P (658.4209)


   

PA(14:0/18:2(9Z,11E)+=O(13))

PA(14:0/18:2(9Z,11E)+=O(13))

C35H63O9P (658.4209)


   

PA(18:2(9Z,11E)+=O(13)/14:0)

PA(18:2(9Z,11E)+=O(13)/14:0)

C35H63O9P (658.4209)


   

PA(14:1(9Z)/18:1(12Z)-O(9S,10R))

PA(14:1(9Z)/18:1(12Z)-O(9S,10R))

C35H63O9P (658.4209)


   

PA(18:1(12Z)-O(9S,10R)/14:1(9Z))

PA(18:1(12Z)-O(9S,10R)/14:1(9Z))

C35H63O9P (658.4209)


   

PA(i-12:0/20:3(6,8,11)-OH(5))

PA(i-12:0/20:3(6,8,11)-OH(5))

C35H63O9P (658.4209)


   

PA(20:3(6,8,11)-OH(5)/i-12:0)

PA(20:3(6,8,11)-OH(5)/i-12:0)

C35H63O9P (658.4209)


   

PA(i-14:0/18:2(10E,12Z)+=O(9))

PA(i-14:0/18:2(10E,12Z)+=O(9))

C35H63O9P (658.4209)


   

PA(18:2(10E,12Z)+=O(9)/i-14:0)

PA(18:2(10E,12Z)+=O(9)/i-14:0)

C35H63O9P (658.4209)


   

PA(i-14:0/18:2(9Z,11E)+=O(13))

PA(i-14:0/18:2(9Z,11E)+=O(13))

C35H63O9P (658.4209)


   

PA(18:2(9Z,11E)+=O(13)/i-14:0)

PA(18:2(9Z,11E)+=O(13)/i-14:0)

C35H63O9P (658.4209)


   

[(2R)-1-dodecanoyloxy-3-phosphonooxypropan-2-yl] (6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoate

[(2R)-1-dodecanoyloxy-3-phosphonooxypropan-2-yl] (6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoate

C35H63O9P (658.4209)


   

[(2R)-2-dodecanoyloxy-3-phosphonooxypropyl] (6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoate

[(2R)-2-dodecanoyloxy-3-phosphonooxypropyl] (6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoate

C35H63O9P (658.4209)


   

[(2R)-1-phosphonooxy-3-tetradecanoyloxypropan-2-yl] (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate

[(2R)-1-phosphonooxy-3-tetradecanoyloxypropan-2-yl] (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate

C35H63O9P (658.4209)


   

[(2R)-3-phosphonooxy-2-tetradecanoyloxypropyl] (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate

[(2R)-3-phosphonooxy-2-tetradecanoyloxypropyl] (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate

C35H63O9P (658.4209)


   

[(2R)-1-phosphonooxy-3-tetradecanoyloxypropan-2-yl] (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate

[(2R)-1-phosphonooxy-3-tetradecanoyloxypropan-2-yl] (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate

C35H63O9P (658.4209)


   

[(2R)-3-phosphonooxy-2-tetradecanoyloxypropyl] (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate

[(2R)-3-phosphonooxy-2-tetradecanoyloxypropyl] (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate

C35H63O9P (658.4209)


   

PA(14:1(9Z)/18:1(9Z)-O(12,13))

PA(14:1(9Z)/18:1(9Z)-O(12,13))

C35H63O9P (658.4209)


   

PA(18:1(9Z)-O(12,13)/14:1(9Z))

PA(18:1(9Z)-O(12,13)/14:1(9Z))

C35H63O9P (658.4209)


   

PA(i-14:0/18:3(10,12,15)-OH(9))

PA(i-14:0/18:3(10,12,15)-OH(9))

C35H63O9P (658.4209)


   

PA(18:3(10,12,15)-OH(9)/i-14:0)

PA(18:3(10,12,15)-OH(9)/i-14:0)

C35H63O9P (658.4209)


   

PA(i-14:0/18:3(9,11,15)-OH(13))

PA(i-14:0/18:3(9,11,15)-OH(13))

C35H63O9P (658.4209)


   

PA(18:3(9,11,15)-OH(13)/i-14:0)

PA(18:3(9,11,15)-OH(13)/i-14:0)

C35H63O9P (658.4209)


   

PA(10:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

PA(10:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

C33H55O11P (658.3482)


   

PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/10:0)

PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/10:0)

C33H55O11P (658.3482)


   

AcChaArgTicMetNH2

AcChaArgTicMetNH2

C32H50N8O5S (658.3625)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoxy]propan-2-yl] undecanoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoxy]propan-2-yl] undecanoate

C35H63O9P (658.4209)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]propan-2-yl] tridecanoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]propan-2-yl] tridecanoate

C35H63O9P (658.4209)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tridec-9-enoxy]propan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tridec-9-enoxy]propan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

C35H63O9P (658.4209)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-undecoxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-undecoxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

C35H63O9P (658.4209)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoxy]propan-2-yl] (Z)-tridec-9-enoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoxy]propan-2-yl] (Z)-tridec-9-enoate

C35H63O9P (658.4209)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-tridecoxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-tridecoxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

C35H63O9P (658.4209)


   

6-[2-dodecanoyloxy-3-[(Z)-tetradec-9-enoyl]oxypropoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid

6-[2-dodecanoyloxy-3-[(Z)-tetradec-9-enoyl]oxypropoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid

C35H62O11 (658.4292)


   

3,4,5-trihydroxy-6-[2-tridecanoyloxy-3-[(Z)-tridec-9-enoyl]oxypropoxy]oxane-2-carboxylic acid

3,4,5-trihydroxy-6-[2-tridecanoyloxy-3-[(Z)-tridec-9-enoyl]oxypropoxy]oxane-2-carboxylic acid

C35H62O11 (658.4292)


   

[1-[(2-acetyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoate

[1-[(2-acetyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoate

C34H59O10P (658.3846)


   

[1-[(2-hexanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate

[1-[(2-hexanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate

C34H59O10P (658.3846)


   

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-octanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-octanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate

C34H59O10P (658.3846)


   

[1-[(2-butanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoate

[1-[(2-butanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoate

C34H59O10P (658.3846)


   

[1-[(2-dodecanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

[1-[(2-dodecanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

C34H59O10P (658.3846)


   

[1-[(2-decanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

[1-[(2-decanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

C34H59O10P (658.3846)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexanoyloxypropan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexanoyloxypropan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate

C34H59O10P (658.3846)


   

[1-butanoyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoate

[1-butanoyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoate

C34H59O10P (658.3846)


   

[1-acetyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoate

[1-acetyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoate

C34H59O10P (658.3846)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-octanoyloxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-octanoyloxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate

C34H59O10P (658.3846)


   

[1-decanoyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

[1-decanoyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

C34H59O10P (658.3846)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-dodecanoyloxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-dodecanoyloxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

C34H59O10P (658.3846)


   

[1-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-phosphonooxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate

[1-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-phosphonooxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate

C37H55O8P (658.3634)


   

[1-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxy-3-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

[1-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxy-3-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

C37H54O10 (658.3717)


   

[(2R)-1-decanoyloxy-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropan-2-yl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate

[(2R)-1-decanoyloxy-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropan-2-yl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate

C34H59O10P (658.3846)


   

[(2R)-1-decanoyloxy-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropan-2-yl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate

[(2R)-1-decanoyloxy-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropan-2-yl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate

C34H59O10P (658.3846)


   

[(2S)-2-decanoyloxy-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropyl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate

[(2S)-2-decanoyloxy-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropyl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate

C34H59O10P (658.3846)


   

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-dodec-5-enoyl]oxypropan-2-yl] (9E,11E,13E)-hexadeca-9,11,13-trienoate

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-dodec-5-enoyl]oxypropan-2-yl] (9E,11E,13E)-hexadeca-9,11,13-trienoate

C34H59O10P (658.3846)


   

[(2S)-2-decanoyloxy-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropyl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate

[(2S)-2-decanoyloxy-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropyl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate

C34H59O10P (658.3846)


   

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-dodecanoyloxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-dodecanoyloxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate

C34H59O10P (658.3846)


   

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(6E,9E)-dodeca-6,9-dienoyl]oxypropan-2-yl] (4E,7E)-hexadeca-4,7-dienoate

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(6E,9E)-dodeca-6,9-dienoyl]oxypropan-2-yl] (4E,7E)-hexadeca-4,7-dienoate

C34H59O10P (658.3846)


   

[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-phosphonooxypropyl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate

[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-phosphonooxypropyl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate

C37H55O8P (658.3634)


   

[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-phosphonooxypropyl] (7E,9E,11E,13E,15E)-octadeca-7,9,11,13,15-pentaenoate

[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-phosphonooxypropyl] (7E,9E,11E,13E,15E)-octadeca-7,9,11,13,15-pentaenoate

C37H55O8P (658.3634)


   

MGDG O-29:8

MGDG O-29:8

C38H58O9 (658.4081)


   
   
   
   
   
   

PA P-20:0/12:3;O2

PA P-20:0/12:3;O2

C35H63O9P (658.4209)


   

PA P-20:1/11:3;O3

PA P-20:1/11:3;O3

C34H59O10P (658.3846)


   

PA P-20:1/12:2;O2

PA P-20:1/12:2;O2

C35H63O9P (658.4209)


   

PA 14:0/18:3;O

PA 14:0/18:3;O

C35H63O9P (658.4209)


   

PA 14:1/18:2;O

PA 14:1/18:2;O

C35H63O9P (658.4209)


   

PA 18:0/13:4;O2

PA 18:0/13:4;O2

C34H59O10P (658.3846)


   

PA 18:1/13:3;O2

PA 18:1/13:3;O2

C34H59O10P (658.3846)


   

PA 18:2/12:3;O3

PA 18:2/12:3;O3

C33H55O11P (658.3482)


   

PA 18:3/12:2;O3

PA 18:3/12:2;O3

C33H55O11P (658.3482)


   

PA 20:0/12:3;O

PA 20:0/12:3;O

C35H63O9P (658.4209)


   
   
   
   
   
   
   

PG O-11:0/18:4

PG O-11:0/18:4

C35H63O9P (658.4209)


   
   
   

PG P-16:1/12:3;O

PG P-16:1/12:3;O

C34H59O10P (658.3846)


   

PG P-18:1/9:4;O2

PG P-18:1/9:4;O2

C33H55O11P (658.3482)


   

PG P-20:1/8:3;O

PG P-20:1/8:3;O

C34H59O10P (658.3846)


   
   
   
   
   
   
   
   
   
   
   
   
   

ST 27:1;O7;GlcA

ST 27:1;O7;GlcA

C33H54O13 (658.3564)


   

ST 28:0;O6;GlcA

ST 28:0;O6;GlcA

C34H58O12 (658.3928)


   

ST 27:2;O8;Hex

ST 27:2;O8;Hex

C33H54O13 (658.3564)


   

ST 28:1;O7;Hex

ST 28:1;O7;Hex

C34H58O12 (658.3928)


   

ST 29:0;O6;Hex

ST 29:0;O6;Hex

C35H62O11 (658.4292)


   

11-hydroxy-1-{1-[3-(hydroxymethyl)-4-methyl-5-oxo-2h-furan-2-yl]propan-2-yl}-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-7-yl 1-methyl 3-hydroxy-3-methylpentanedioate

11-hydroxy-1-{1-[3-(hydroxymethyl)-4-methyl-5-oxo-2h-furan-2-yl]propan-2-yl}-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-7-yl 1-methyl 3-hydroxy-3-methylpentanedioate

C38H58O9 (658.4081)


   

(1r,3as,5ar,7r,9as,11s,11ar)-11-hydroxy-1-[(2r)-1-[(2s)-3-(hydroxymethyl)-4-methyl-5-oxo-2h-furan-2-yl]propan-2-yl]-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-7-yl 1-methyl (3s)-3-hydroxy-3-methylpentanedioate

(1r,3as,5ar,7r,9as,11s,11ar)-11-hydroxy-1-[(2r)-1-[(2s)-3-(hydroxymethyl)-4-methyl-5-oxo-2h-furan-2-yl]propan-2-yl]-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-7-yl 1-methyl (3s)-3-hydroxy-3-methylpentanedioate

C38H58O9 (658.4081)


   

(1r,1's,2s,4'r,5r,5'r,6'r,10's,12'r,16's,18's,20'r,21's)-4',5,6',12',17',17'-hexamethyl-18'-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-3,6,9'-trioxaspiro[bicyclo[3.1.0]hexane-2,8'-hexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan]-13'-en-20'-yl acetate

(1r,1's,2s,4'r,5r,5'r,6'r,10's,12'r,16's,18's,20'r,21's)-4',5,6',12',17',17'-hexamethyl-18'-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-3,6,9'-trioxaspiro[bicyclo[3.1.0]hexane-2,8'-hexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan]-13'-en-20'-yl acetate

C37H54O10 (658.3717)


   

(1s,3r,6s,8r,12s,15r,16r,17r)-15-[(2r)-4-[(2r)-3,3-dimethyloxiran-2-yl]-4-oxobutan-2-yl]-7,7,12,16-tetramethyl-14-oxo-6-{[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadec-10-en-17-yl acetate

(1s,3r,6s,8r,12s,15r,16r,17r)-15-[(2r)-4-[(2r)-3,3-dimethyloxiran-2-yl]-4-oxobutan-2-yl]-7,7,12,16-tetramethyl-14-oxo-6-{[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadec-10-en-17-yl acetate

C37H54O10 (658.3717)


   

3-{5,9,12-trihydroxy-6,13-dimethyl-10-methylidene-2-oxo-14-[(5e,7e)-3,7,11-trimethyl-4-oxoheptadeca-5,7-dien-1-yl]-1-oxa-4,8,11-triazacyclotetradeca-4,8,11-trien-3-yl}propanimidic acid

3-{5,9,12-trihydroxy-6,13-dimethyl-10-methylidene-2-oxo-14-[(5e,7e)-3,7,11-trimethyl-4-oxoheptadeca-5,7-dien-1-yl]-1-oxa-4,8,11-triazacyclotetradeca-4,8,11-trien-3-yl}propanimidic acid

C36H58N4O7 (658.4305)


   

2-[(7-ethenyl-2,3-dihydroxy-1,4a,4b,7-tetramethyl-2,3,4,5,6,8,10,10a-octahydrophenanthren-1-yl)methoxy]-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxane-3,4,5-triol

2-[(7-ethenyl-2,3-dihydroxy-1,4a,4b,7-tetramethyl-2,3,4,5,6,8,10,10a-octahydrophenanthren-1-yl)methoxy]-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxane-3,4,5-triol

C33H54O13 (658.3564)


   

(4as,4'as,9s,9's,10as,10'as)-6,6'-dihydroxy-7,7'-diisopropyl-1,1,1',1',4a,4'a-hexamethyl-2h,2'h,3h,3'h,4h,4'h,9h,9'h,10ah,10'ah-[9,9'-biphenanthrene]-5,5',8,8',10,10'-hexone

(4as,4'as,9s,9's,10as,10'as)-6,6'-dihydroxy-7,7'-diisopropyl-1,1,1',1',4a,4'a-hexamethyl-2h,2'h,3h,3'h,4h,4'h,9h,9'h,10ah,10'ah-[9,9'-biphenanthrene]-5,5',8,8',10,10'-hexone

C40H50O8 (658.3506)


   

(1s,3as,5as,7r,8s,9r,9ar,9br,11ar)-3a,8,9-trihydroxy-9a,11a-dimethyl-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1-[(2r,3r)-2,3,6-trihydroxy-6-methylheptan-2-yl]-1h,2h,3h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-5-one

(1s,3as,5as,7r,8s,9r,9ar,9br,11ar)-3a,8,9-trihydroxy-9a,11a-dimethyl-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1-[(2r,3r)-2,3,6-trihydroxy-6-methylheptan-2-yl]-1h,2h,3h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-5-one

C33H54O13 (658.3564)


   

1-(3a-hydroxy-9a,11a-dimethyl-7-{[3,4,5-trihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-tetradecahydrocyclopenta[a]phenanthren-1-yl)ethanone

1-(3a-hydroxy-9a,11a-dimethyl-7-{[3,4,5-trihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-tetradecahydrocyclopenta[a]phenanthren-1-yl)ethanone

C33H54O13 (658.3564)


   

(1s,3s)-3-hydroxy-4-[(3e,5e,7e,9e,11e,13e,15e)-18-[(1s,4s,6r)-4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl]-3,7,12,16-tetramethyl-17-oxooctadeca-1,3,5,7,9,11,13,15-octaen-1-ylidene]-3,5,5-trimethylcyclohexyl acetate

(1s,3s)-3-hydroxy-4-[(3e,5e,7e,9e,11e,13e,15e)-18-[(1s,4s,6r)-4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl]-3,7,12,16-tetramethyl-17-oxooctadeca-1,3,5,7,9,11,13,15-octaen-1-ylidene]-3,5,5-trimethylcyclohexyl acetate

C42H58O6 (658.4233)


   

(1s,3as,5as,7r,8s,9r,9ar,9br,11ar)-1-[(2r,3r)-2,6-dihydroxy-6-methyl-3-{[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}heptan-2-yl]-3a,7,8,9-tetrahydroxy-9a,11a-dimethyl-1h,2h,3h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-5-one

(1s,3as,5as,7r,8s,9r,9ar,9br,11ar)-1-[(2r,3r)-2,6-dihydroxy-6-methyl-3-{[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}heptan-2-yl]-3a,7,8,9-tetrahydroxy-9a,11a-dimethyl-1h,2h,3h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-5-one

C33H54O13 (658.3564)


   

20-hydroxyecdysone 3-o-β-d-glucoside

NA

C33H54O13 (658.3564)


{"Ingredient_id": "HBIN003414","Ingredient_name": "20-hydroxyecdysone 3-o-\u03b2-d-glucoside","Alias": "NA","Ingredient_formula": "C33H54O13","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "10063","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

(1'r,2s,3r,4s,4's,5r,6r,8'r,10'z,13'r,14'z,16'z,20'r,21'r,24's)-6-ethyl-3,21',24'-trihydroxy-5,11',13',22'-tetramethyl-2'-oxo-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-4-yl 2-methylbutanoate

(1'r,2s,3r,4s,4's,5r,6r,8'r,10'z,13'r,14'z,16'z,20'r,21'r,24's)-6-ethyl-3,21',24'-trihydroxy-5,11',13',22'-tetramethyl-2'-oxo-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-4-yl 2-methylbutanoate

C37H54O10 (658.3717)


   

6,6'-dihydroxy-7,7'-diisopropyl-1,1,1',1',4a,4'a-hexamethyl-2h,2'h,3h,3'h,4h,4'h,9h,9'h,10ah,10'ah-[9,9'-biphenanthrene]-5,5',8,8',10,10'-hexone

6,6'-dihydroxy-7,7'-diisopropyl-1,1,1',1',4a,4'a-hexamethyl-2h,2'h,3h,3'h,4h,4'h,9h,9'h,10ah,10'ah-[9,9'-biphenanthrene]-5,5',8,8',10,10'-hexone

C40H50O8 (658.3506)


   

1-(2,6-dihydroxy-6-methyl-3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}heptan-2-yl)-3a,7,8,9-tetrahydroxy-9a,11a-dimethyl-1h,2h,3h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-5-one

1-(2,6-dihydroxy-6-methyl-3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}heptan-2-yl)-3a,7,8,9-tetrahydroxy-9a,11a-dimethyl-1h,2h,3h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-5-one

C33H54O13 (658.3564)


   

(4as,4'as,9s,9's,10as,10'as)-8,8'-dihydroxy-7,7'-diisopropyl-1,1,1',1',4a,4'a-hexamethyl-2h,2'h,3h,3'h,4h,4'h,9h,9'h,10ah,10'ah-[9,9'-biphenanthrene]-5,5',6,6',10,10'-hexone

(4as,4'as,9s,9's,10as,10'as)-8,8'-dihydroxy-7,7'-diisopropyl-1,1,1',1',4a,4'a-hexamethyl-2h,2'h,3h,3'h,4h,4'h,9h,9'h,10ah,10'ah-[9,9'-biphenanthrene]-5,5',6,6',10,10'-hexone

C40H50O8 (658.3506)


   

3-hydroxy-4-[(5e,7e,9e,11e,13e,15e)-18-{4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl}-3,7,12,16-tetramethyl-17-oxooctadeca-1,3,5,7,9,11,13,15-octaen-1-ylidene]-3,5,5-trimethylcyclohexyl acetate

3-hydroxy-4-[(5e,7e,9e,11e,13e,15e)-18-{4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl}-3,7,12,16-tetramethyl-17-oxooctadeca-1,3,5,7,9,11,13,15-octaen-1-ylidene]-3,5,5-trimethylcyclohexyl acetate

C42H58O6 (658.4233)


   

(7r,8ar,10ar)-5-{2-[(7r,8ar,10ar)-2,7-dihydroxy-1-isopropyl-8a,10a-dimethyl-3,6-dioxo-7h,8h,9h,10h-cyclohexa[f]azulen-5-yl]ethyl}-2,7-dihydroxy-1-isopropyl-8a,10a-dimethyl-7h,8h,9h,10h-cyclohexa[f]azulene-3,6-dione

(7r,8ar,10ar)-5-{2-[(7r,8ar,10ar)-2,7-dihydroxy-1-isopropyl-8a,10a-dimethyl-3,6-dioxo-7h,8h,9h,10h-cyclohexa[f]azulen-5-yl]ethyl}-2,7-dihydroxy-1-isopropyl-8a,10a-dimethyl-7h,8h,9h,10h-cyclohexa[f]azulene-3,6-dione

C40H50O8 (658.3506)


   

2-[1-(2-hydroxy-9a,11a-dimethyl-7-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl)ethoxy]-6-(hydroxymethyl)oxane-3,4,5-triol

2-[1-(2-hydroxy-9a,11a-dimethyl-7-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl)ethoxy]-6-(hydroxymethyl)oxane-3,4,5-triol

C33H54O13 (658.3564)


   

6-ethyl-3,21',24'-trihydroxy-5,11',13',22'-tetramethyl-2'-oxo-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-4-yl 2-methylbutanoate

6-ethyl-3,21',24'-trihydroxy-5,11',13',22'-tetramethyl-2'-oxo-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-4-yl 2-methylbutanoate

C37H54O10 (658.3717)


   

(1s,3r,6s,8r,12s,15r,16r,17r)-15-[(2r)-4-[(2r)-3,3-dimethyloxiran-2-yl]-4-oxobutan-2-yl]-7,7,12,16-tetramethyl-14-oxo-6-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadec-10-en-17-yl acetate

(1s,3r,6s,8r,12s,15r,16r,17r)-15-[(2r)-4-[(2r)-3,3-dimethyloxiran-2-yl]-4-oxobutan-2-yl]-7,7,12,16-tetramethyl-14-oxo-6-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadec-10-en-17-yl acetate

C37H54O10 (658.3717)


   

1-[(1s,3as,3br,5as,7s,9as,9bs,11ar)-3a-hydroxy-9a,11a-dimethyl-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-tetradecahydrocyclopenta[a]phenanthren-1-yl]ethanone

1-[(1s,3as,3br,5as,7s,9as,9bs,11ar)-3a-hydroxy-9a,11a-dimethyl-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-tetradecahydrocyclopenta[a]phenanthren-1-yl]ethanone

C33H54O13 (658.3564)


   

10,11-bis(acetyloxy)-9-[(acetyloxy)methyl]-4a-(methoxycarbonyl)-2,6a,6b,9,12a-pentamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-2-carboxylic acid

10,11-bis(acetyloxy)-9-[(acetyloxy)methyl]-4a-(methoxycarbonyl)-2,6a,6b,9,12a-pentamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-2-carboxylic acid

C37H54O10 (658.3717)


   

(3e,5s,6s,7s,9r,15r,16r)-15-{[(2s,3r,4r,5r,6r)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxy}-6-{[(2s,3r,4s,6r)-3-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-5,7,9,16-tetramethyl-1-oxacyclohexadec-3-ene-2,10-dione

(3e,5s,6s,7s,9r,15r,16r)-15-{[(2s,3r,4r,5r,6r)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxy}-6-{[(2s,3r,4s,6r)-3-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-5,7,9,16-tetramethyl-1-oxacyclohexadec-3-ene-2,10-dione

C34H58O12 (658.3928)


   

[2,3-bis(acetyloxy)-4-[(acetyloxy)methyl]-12-hydroxy-6a,6b,8a,11,12,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicen-4-yl]methyl acetate

[2,3-bis(acetyloxy)-4-[(acetyloxy)methyl]-12-hydroxy-6a,6b,8a,11,12,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicen-4-yl]methyl acetate

C38H58O9 (658.4081)


   

(8r,13e,14s,16s,17s,18s)-17-[(1e)-2-[(1s,12s,13r,18r)-3,20-dimethyl-15-oxa-3,20-diazapentacyclo[10.7.1.0²,¹⁰.0⁴,⁹.0¹³,¹⁸]icosa-2(10),4,6,8,16-pentaen-17-yl]ethenyl]-13-ethylidene-18-(methoxycarbonyl)-1,11-diazapentacyclo[12.3.1.0²,⁷.0⁸,¹⁷.0¹¹,¹⁶]octadeca-2,4,6-trien-11-ium-11-olate

(8r,13e,14s,16s,17s,18s)-17-[(1e)-2-[(1s,12s,13r,18r)-3,20-dimethyl-15-oxa-3,20-diazapentacyclo[10.7.1.0²,¹⁰.0⁴,⁹.0¹³,¹⁸]icosa-2(10),4,6,8,16-pentaen-17-yl]ethenyl]-13-ethylidene-18-(methoxycarbonyl)-1,11-diazapentacyclo[12.3.1.0²,⁷.0⁸,¹⁷.0¹¹,¹⁶]octadeca-2,4,6-trien-11-ium-11-olate

C41H46N4O4 (658.3519)


   

4-[(3e,5e,7e,9e,11e,13e,15e)-18-[(1e)-2,4-dihydroxy-2,6,6-trimethylcyclohexylidene]-3,7,12,16-tetramethyl-17-oxooctadeca-1,3,5,7,9,11,13,15-octaen-1-ylidene]-3-hydroxy-3,5,5-trimethylcyclohexyl acetate

4-[(3e,5e,7e,9e,11e,13e,15e)-18-[(1e)-2,4-dihydroxy-2,6,6-trimethylcyclohexylidene]-3,7,12,16-tetramethyl-17-oxooctadeca-1,3,5,7,9,11,13,15-octaen-1-ylidene]-3-hydroxy-3,5,5-trimethylcyclohexyl acetate

C42H58O6 (658.4233)


   

2-{[1-hydroxy-1-(1-hydroxyethyl)-9a,11a-dimethyl-2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxane-3,4,5-triol

2-{[1-hydroxy-1-(1-hydroxyethyl)-9a,11a-dimethyl-2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxane-3,4,5-triol

C33H54O13 (658.3564)


   

3a,8,9-trihydroxy-9a,11a-dimethyl-7-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1-(2,3,6-trihydroxy-6-methylheptan-2-yl)-1h,2h,3h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-5-one

3a,8,9-trihydroxy-9a,11a-dimethyl-7-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1-(2,3,6-trihydroxy-6-methylheptan-2-yl)-1h,2h,3h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-5-one

C33H54O13 (658.3564)


   

9a,11a-dimethyl-1-[6-methyl-5-(2-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}ethyl)heptan-2-yl]-dodecahydro-1h-cyclopenta[a]phenanthrene-3,3b,5,5a,7-pentol

9a,11a-dimethyl-1-[6-methyl-5-(2-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}ethyl)heptan-2-yl]-dodecahydro-1h-cyclopenta[a]phenanthrene-3,3b,5,5a,7-pentol

C35H62O11 (658.4292)


   

(1s,2s,6r,10s,11r,13s,14r,15r)-13-(acetyloxy)-1,6-dihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5,9-dioxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,7-dien-14-yl hexadecanoate

(1s,2s,6r,10s,11r,13s,14r,15r)-13-(acetyloxy)-1,6-dihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5,9-dioxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,7-dien-14-yl hexadecanoate

C38H58O9 (658.4081)


   

acutissimatriterpene a

acutissimatriterpene a

C40H50O8 (658.3506)


   

5-(acetyloxy)-6-[3,7-bis(acetyloxy)-4-ethoxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-2-methylhept-2-enoic acid

5-(acetyloxy)-6-[3,7-bis(acetyloxy)-4-ethoxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-2-methylhept-2-enoic acid

C38H58O9 (658.4081)


   

4',5,6',12',17',17'-hexamethyl-18'-[(3,4,5-trihydroxyoxan-2-yl)oxy]-3,6,9'-trioxaspiro[bicyclo[3.1.0]hexane-2,8'-hexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan]-13'-en-20'-yl acetate

4',5,6',12',17',17'-hexamethyl-18'-[(3,4,5-trihydroxyoxan-2-yl)oxy]-3,6,9'-trioxaspiro[bicyclo[3.1.0]hexane-2,8'-hexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan]-13'-en-20'-yl acetate

C37H54O10 (658.3717)


   

(1r,2r,3s,3as,3bs,5s,5as,6r,7s,9as,9br,11ar)-1-[(2r,5r)-5-(2-{[(2r,3r,4r,5r)-3,4-dihydroxy-5-methoxyoxan-2-yl]oxy}ethyl)-6-methylheptan-2-yl]-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthrene-2,3,3b,5,6,7-hexol

(1r,2r,3s,3as,3bs,5s,5as,6r,7s,9as,9br,11ar)-1-[(2r,5r)-5-(2-{[(2r,3r,4r,5r)-3,4-dihydroxy-5-methoxyoxan-2-yl]oxy}ethyl)-6-methylheptan-2-yl]-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthrene-2,3,3b,5,6,7-hexol

C35H62O11 (658.4292)


   

2-[(6-{[3a-hydroxy-1-(1-hydroxyethyl)-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-7-yl]oxy}-5-hydroxy-4-methoxy-2-methyloxan-3-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol

2-[(6-{[3a-hydroxy-1-(1-hydroxyethyl)-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-7-yl]oxy}-5-hydroxy-4-methoxy-2-methyloxan-3-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol

C34H58O12 (658.3928)


   

(2r,3r,4s,5s,6r)-2-{[(1r,3as,3br,7s,9ar,9bs,11as)-1-hydroxy-1-[(1s)-1-hydroxyethyl]-9a,11a-dimethyl-2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-6-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxane-3,4,5-triol

(2r,3r,4s,5s,6r)-2-{[(1r,3as,3br,7s,9ar,9bs,11as)-1-hydroxy-1-[(1s)-1-hydroxyethyl]-9a,11a-dimethyl-2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-6-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxane-3,4,5-triol

C33H54O13 (658.3564)


   

(1s,3r,6s,8r,12s,15r,16r,17r)-15-[(2r)-4-[(2s)-3,3-dimethyloxiran-2-yl]-4-oxobutan-2-yl]-7,7,12,16-tetramethyl-14-oxo-6-{[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadec-10-en-17-yl acetate

(1s,3r,6s,8r,12s,15r,16r,17r)-15-[(2r)-4-[(2s)-3,3-dimethyloxiran-2-yl]-4-oxobutan-2-yl]-7,7,12,16-tetramethyl-14-oxo-6-{[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadec-10-en-17-yl acetate

C37H54O10 (658.3717)


   

3-[5,9,12-trihydroxy-6,13-dimethyl-10-methylidene-2-oxo-14-(3,7,11-trimethyl-4-oxoheptadeca-5,7-dien-1-yl)-1-oxa-4,8,11-triazacyclotetradeca-4,8,11-trien-3-yl]propanimidic acid

3-[5,9,12-trihydroxy-6,13-dimethyl-10-methylidene-2-oxo-14-(3,7,11-trimethyl-4-oxoheptadeca-5,7-dien-1-yl)-1-oxa-4,8,11-triazacyclotetradeca-4,8,11-trien-3-yl]propanimidic acid

C36H58N4O7 (658.4305)


   

[(3s,4s,4ar,6ar,6bs,8r,8ar,9r,12as,14ar,14br)-3,9-bis(acetyloxy)-8a-[(acetyloxy)methyl]-8-hydroxy-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-4-yl]methyl acetate

[(3s,4s,4ar,6ar,6bs,8r,8ar,9r,12as,14ar,14br)-3,9-bis(acetyloxy)-8a-[(acetyloxy)methyl]-8-hydroxy-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-4-yl]methyl acetate

C38H58O9 (658.4081)


   

9a-{3,4a,5-trimethyl-6-[(2-methylbut-2-enoyl)oxy]-2-oxo-4h,5h,6h,7h,8h-naphtho[2,3-b]furan-9a-yl}-3,4a,5-trimethyl-2-oxo-4h,5h,6h,7h,8h-naphtho[2,3-b]furan-6-yl 2-methylbut-2-enoate

9a-{3,4a,5-trimethyl-6-[(2-methylbut-2-enoyl)oxy]-2-oxo-4h,5h,6h,7h,8h-naphtho[2,3-b]furan-9a-yl}-3,4a,5-trimethyl-2-oxo-4h,5h,6h,7h,8h-naphtho[2,3-b]furan-6-yl 2-methylbut-2-enoate

C40H50O8 (658.3506)


   

(4ar,5r,6s,9ar)-9a-[(4ar,5r,6s,9ar)-3,4a,5-trimethyl-6-{[(2z)-2-methylbut-2-enoyl]oxy}-2-oxo-4h,5h,6h,7h,8h-naphtho[2,3-b]furan-9a-yl]-3,4a,5-trimethyl-2-oxo-4h,5h,6h,7h,8h-naphtho[2,3-b]furan-6-yl (2z)-2-methylbut-2-enoate

(4ar,5r,6s,9ar)-9a-[(4ar,5r,6s,9ar)-3,4a,5-trimethyl-6-{[(2z)-2-methylbut-2-enoyl]oxy}-2-oxo-4h,5h,6h,7h,8h-naphtho[2,3-b]furan-9a-yl]-3,4a,5-trimethyl-2-oxo-4h,5h,6h,7h,8h-naphtho[2,3-b]furan-6-yl (2z)-2-methylbut-2-enoate

C40H50O8 (658.3506)


   

[(2s,3r,4r,5s,6r)-3-ethyl-6-[(2s,3s,4s,6r)-6-[(2s,2'r,3'r,4s,5s,5'r)-5'-ethyl-2'-hydroxy-5'-[(1s)-1-hydroxypropyl]-2,3',4-trimethyl-[2,2'-bioxolan]-5-yl]-3-hydroxy-4-methyl-5-oxooctan-2-yl]-2,4-dihydroxy-5-methyloxan-2-yl]acetic acid

[(2s,3r,4r,5s,6r)-3-ethyl-6-[(2s,3s,4s,6r)-6-[(2s,2'r,3'r,4s,5s,5'r)-5'-ethyl-2'-hydroxy-5'-[(1s)-1-hydroxypropyl]-2,3',4-trimethyl-[2,2'-bioxolan]-5-yl]-3-hydroxy-4-methyl-5-oxooctan-2-yl]-2,4-dihydroxy-5-methyloxan-2-yl]acetic acid

C35H62O11 (658.4292)


   

1,3-bis[(4r,4as,6r,7s,7as)-2,4,7-trimethyl-octahydrocyclopenta[c]pyridin-6-yl] (1r,2r,3r,4s)-2,4-bis(4-hydroxyphenyl)cyclobutane-1,3-dicarboxylate

1,3-bis[(4r,4as,6r,7s,7as)-2,4,7-trimethyl-octahydrocyclopenta[c]pyridin-6-yl] (1r,2r,3r,4s)-2,4-bis(4-hydroxyphenyl)cyclobutane-1,3-dicarboxylate

C40H54N2O6 (658.3982)


   

2-[(4-{[3a,10-dihydroxy-9a,11a-dimethyl-1-(6-oxopyran-3-yl)-tetradecahydrocyclopenta[a]phenanthren-7-yl]oxy}-1-hydroxy-4-oxobutylidene)amino]-5-carbamimidamidopentanoic acid

2-[(4-{[3a,10-dihydroxy-9a,11a-dimethyl-1-(6-oxopyran-3-yl)-tetradecahydrocyclopenta[a]phenanthren-7-yl]oxy}-1-hydroxy-4-oxobutylidene)amino]-5-carbamimidamidopentanoic acid

C34H50N4O9 (658.3578)


   

(2e,6s)-6-[(1r,3s,3ar,4r,5ar,7r,9as,11ar)-3,7-bis(acetyloxy)-4-ethoxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-(acetyloxy)-2-methylhept-2-enoic acid

(2e,6s)-6-[(1r,3s,3ar,4r,5ar,7r,9as,11ar)-3,7-bis(acetyloxy)-4-ethoxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-(acetyloxy)-2-methylhept-2-enoic acid

C38H58O9 (658.4081)


   

(1s,3as,5as,7r,8s,9ar,9br,11ar)-3a,5a,8-trihydroxy-9a,11a-dimethyl-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1-[(2r,3r)-2,3,6-trihydroxy-6-methylheptan-2-yl]-1h,2h,3h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-5-one

(1s,3as,5as,7r,8s,9ar,9br,11ar)-3a,5a,8-trihydroxy-9a,11a-dimethyl-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1-[(2r,3r)-2,3,6-trihydroxy-6-methylheptan-2-yl]-1h,2h,3h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-5-one

C33H54O13 (658.3564)


   

15-[4-(3,3-dimethyloxiran-2-yl)-4-oxobutan-2-yl]-7,7,12,16-tetramethyl-14-oxo-6-[(3,4,5-trihydroxyoxan-2-yl)oxy]pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadec-10-en-17-yl acetate

15-[4-(3,3-dimethyloxiran-2-yl)-4-oxobutan-2-yl]-7,7,12,16-tetramethyl-14-oxo-6-[(3,4,5-trihydroxyoxan-2-yl)oxy]pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadec-10-en-17-yl acetate

C37H54O10 (658.3717)


   

(2s,4ar,6as,6br,8ar,9r,10r,11s,12ar,12br,14bs)-10,11-bis(acetyloxy)-9-[(acetyloxy)methyl]-4a-(methoxycarbonyl)-2,6a,6b,9,12a-pentamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-2-carboxylic acid

(2s,4ar,6as,6br,8ar,9r,10r,11s,12ar,12br,14bs)-10,11-bis(acetyloxy)-9-[(acetyloxy)methyl]-4a-(methoxycarbonyl)-2,6a,6b,9,12a-pentamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-2-carboxylic acid

C37H54O10 (658.3717)


   

4',5,6',12',17',17'-hexamethyl-18'-[(3,4,5-trihydroxyoxan-2-yl)oxy]-3,6,9'-trioxaspiro[bicyclo[3.1.0]hexane-2,8'-hexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan]-14'-en-3'-yl acetate

4',5,6',12',17',17'-hexamethyl-18'-[(3,4,5-trihydroxyoxan-2-yl)oxy]-3,6,9'-trioxaspiro[bicyclo[3.1.0]hexane-2,8'-hexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan]-14'-en-3'-yl acetate

C37H54O10 (658.3717)


   

(4as,4'as,9r,9's,10as,10'as)-6,6'-dihydroxy-7,7'-diisopropyl-1,1,1',1',4a,4'a-hexamethyl-2h,2'h,3h,3'h,4h,4'h,9h,9'h,10ah,10'ah-[9,9'-biphenanthrene]-5,5',8,8',10,10'-hexone

(4as,4'as,9r,9's,10as,10'as)-6,6'-dihydroxy-7,7'-diisopropyl-1,1,1',1',4a,4'a-hexamethyl-2h,2'h,3h,3'h,4h,4'h,9h,9'h,10ah,10'ah-[9,9'-biphenanthrene]-5,5',8,8',10,10'-hexone

C40H50O8 (658.3506)


   

1,3-bis[(4r,4as,6r,7s,7ar)-2,4,7-trimethyl-octahydrocyclopenta[c]pyridin-6-yl] (1r,2r,3s,4s)-2,4-bis(4-hydroxyphenyl)cyclobutane-1,3-dicarboxylate

1,3-bis[(4r,4as,6r,7s,7ar)-2,4,7-trimethyl-octahydrocyclopenta[c]pyridin-6-yl] (1r,2r,3s,4s)-2,4-bis(4-hydroxyphenyl)cyclobutane-1,3-dicarboxylate

C40H54N2O6 (658.3982)


   

(6s,12s,15s,18s,21s)-12,15-dibenzyl-18-[(2s)-butan-2-yl]-5,14,17,20-tetrahydroxy-1,4,10,13,16,19-hexaazatricyclo[19.3.0.0⁶,¹⁰]tetracosa-4,13,16,19-tetraene-2,11-dione

(6s,12s,15s,18s,21s)-12,15-dibenzyl-18-[(2s)-butan-2-yl]-5,14,17,20-tetrahydroxy-1,4,10,13,16,19-hexaazatricyclo[19.3.0.0⁶,¹⁰]tetracosa-4,13,16,19-tetraene-2,11-dione

C36H46N6O6 (658.3479)


   

(5r,8r)-3-[(1s,2r,3r,5r,6r,9s,14s,15r,18r,19r)-9-(2h-1,3-benzodioxol-5-yl)-3-hydroxy-2,6,14-trimethyl-8-oxahexacyclo[16.3.1.0¹,¹⁸.0²,¹⁵.0⁵,¹⁴.0⁶,¹¹]docos-11-en-19-yl]-8-methoxy-8-methyl-1,6-dioxaspiro[4.4]non-3-en-2-one

(5r,8r)-3-[(1s,2r,3r,5r,6r,9s,14s,15r,18r,19r)-9-(2h-1,3-benzodioxol-5-yl)-3-hydroxy-2,6,14-trimethyl-8-oxahexacyclo[16.3.1.0¹,¹⁸.0²,¹⁵.0⁵,¹⁴.0⁶,¹¹]docos-11-en-19-yl]-8-methoxy-8-methyl-1,6-dioxaspiro[4.4]non-3-en-2-one

C40H50O8 (658.3506)


   

1,3-bis[(4r,4as,6r,7s,7ar)-2,4,7-trimethyl-octahydrocyclopenta[c]pyridin-6-yl] 2,4-bis(4-hydroxyphenyl)cyclobutane-1,3-dicarboxylate

1,3-bis[(4r,4as,6r,7s,7ar)-2,4,7-trimethyl-octahydrocyclopenta[c]pyridin-6-yl] 2,4-bis(4-hydroxyphenyl)cyclobutane-1,3-dicarboxylate

C40H54N2O6 (658.3982)


   

(2e,5s,6s)-6-[(1r,3s,3ar,4r,5ar,7r,9as,11ar)-3,7-bis(acetyloxy)-4-ethoxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-(acetyloxy)-2-methylhept-2-enoic acid

(2e,5s,6s)-6-[(1r,3s,3ar,4r,5ar,7r,9as,11ar)-3,7-bis(acetyloxy)-4-ethoxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-(acetyloxy)-2-methylhept-2-enoic acid

C38H58O9 (658.4081)


   

13-(acetyloxy)-1,6-dihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5,9-dioxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,7-dien-14-yl hexadecanoate

13-(acetyloxy)-1,6-dihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5,9-dioxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,7-dien-14-yl hexadecanoate

C38H58O9 (658.4081)


   

5-(2-{2,7-dihydroxy-1-isopropyl-8a,10a-dimethyl-3,6-dioxo-7h,8h,9h,10h-cyclohexa[f]azulen-5-yl}ethyl)-2,7-dihydroxy-1-isopropyl-8a,10a-dimethyl-7h,8h,9h,10h-cyclohexa[f]azulene-3,6-dione

5-(2-{2,7-dihydroxy-1-isopropyl-8a,10a-dimethyl-3,6-dioxo-7h,8h,9h,10h-cyclohexa[f]azulen-5-yl}ethyl)-2,7-dihydroxy-1-isopropyl-8a,10a-dimethyl-7h,8h,9h,10h-cyclohexa[f]azulene-3,6-dione

C40H50O8 (658.3506)


   

(1s,3s)-3-hydroxy-4-[(3z,5e,7e,9e,11e,13e,15e)-18-[(1s,4s,6r)-4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl]-3,7,12,16-tetramethyl-17-oxooctadeca-1,3,5,7,9,11,13,15-octaen-1-ylidene]-3,5,5-trimethylcyclohexyl acetate

(1s,3s)-3-hydroxy-4-[(3z,5e,7e,9e,11e,13e,15e)-18-[(1s,4s,6r)-4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl]-3,7,12,16-tetramethyl-17-oxooctadeca-1,3,5,7,9,11,13,15-octaen-1-ylidene]-3,5,5-trimethylcyclohexyl acetate

C42H58O6 (658.4233)


   

(1s,3as,5ar,7r,8r,9s,9ar,9br,11ar)-1-[(2r,3r)-2,6-dihydroxy-6-methyl-3-{[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}heptan-2-yl]-3a,7,8,9-tetrahydroxy-9a,11a-dimethyl-1h,2h,3h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-5-one

(1s,3as,5ar,7r,8r,9s,9ar,9br,11ar)-1-[(2r,3r)-2,6-dihydroxy-6-methyl-3-{[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}heptan-2-yl]-3a,7,8,9-tetrahydroxy-9a,11a-dimethyl-1h,2h,3h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-5-one

C33H54O13 (658.3564)


   

(2s)-2-[(4-{[(1r,3as,3br,5ar,7s,9as,9bs,10r,11ar)-3a,10-dihydroxy-9a,11a-dimethyl-1-(6-oxopyran-3-yl)-tetradecahydrocyclopenta[a]phenanthren-7-yl]oxy}-1-hydroxy-4-oxobutylidene)amino]-5-carbamimidamidopentanoic acid

(2s)-2-[(4-{[(1r,3as,3br,5ar,7s,9as,9bs,10r,11ar)-3a,10-dihydroxy-9a,11a-dimethyl-1-(6-oxopyran-3-yl)-tetradecahydrocyclopenta[a]phenanthren-7-yl]oxy}-1-hydroxy-4-oxobutylidene)amino]-5-carbamimidamidopentanoic acid

C34H50N4O9 (658.3578)


   

[(2r,3r,4ar,6ar,6bs,8ar,11r,12r,12ar,14ar,14br)-2,3-bis(acetyloxy)-4-[(acetyloxy)methyl]-12-hydroxy-6a,6b,8a,11,12,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicen-4-yl]methyl acetate

[(2r,3r,4ar,6ar,6bs,8ar,11r,12r,12ar,14ar,14br)-2,3-bis(acetyloxy)-4-[(acetyloxy)methyl]-12-hydroxy-6a,6b,8a,11,12,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicen-4-yl]methyl acetate

C38H58O9 (658.4081)


   

1,3-bis({2,4,7-trimethyl-octahydrocyclopenta[c]pyridin-6-yl}) 2,4-bis(4-hydroxyphenyl)cyclobutane-1,3-dicarboxylate

1,3-bis({2,4,7-trimethyl-octahydrocyclopenta[c]pyridin-6-yl}) 2,4-bis(4-hydroxyphenyl)cyclobutane-1,3-dicarboxylate

C40H54N2O6 (658.3982)


   

(2r,3r,4s,5s,6r)-2-[(1s)-1-[(1r,2r,3as,3bs,7s,9ar,9bs,11as)-2-hydroxy-9a,11a-dimethyl-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethoxy]-6-(hydroxymethyl)oxane-3,4,5-triol

(2r,3r,4s,5s,6r)-2-[(1s)-1-[(1r,2r,3as,3bs,7s,9ar,9bs,11as)-2-hydroxy-9a,11a-dimethyl-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethoxy]-6-(hydroxymethyl)oxane-3,4,5-triol

C33H54O13 (658.3564)


   

(2r,3s,4r,5s,6r)-2-{[(1s,2r,3r,4as,4bs,7s,10ar)-7-ethenyl-2,3-dihydroxy-1,4a,4b,7-tetramethyl-2,3,4,5,6,8,10,10a-octahydrophenanthren-1-yl]methoxy}-6-({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxane-3,4,5-triol

(2r,3s,4r,5s,6r)-2-{[(1s,2r,3r,4as,4bs,7s,10ar)-7-ethenyl-2,3-dihydroxy-1,4a,4b,7-tetramethyl-2,3,4,5,6,8,10,10a-octahydrophenanthren-1-yl]methoxy}-6-({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxane-3,4,5-triol

C33H54O13 (658.3564)


   

(1r,3s,3as,3bs,5r,5ar,7s,9ar,9br,11ar)-9a,11a-dimethyl-1-[(2r,5r)-6-methyl-5-(2-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}ethyl)heptan-2-yl]-dodecahydro-1h-cyclopenta[a]phenanthrene-3,3b,5,5a,7-pentol

(1r,3s,3as,3bs,5r,5ar,7s,9ar,9br,11ar)-9a,11a-dimethyl-1-[(2r,5r)-6-methyl-5-(2-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}ethyl)heptan-2-yl]-dodecahydro-1h-cyclopenta[a]phenanthrene-3,3b,5,5a,7-pentol

C35H62O11 (658.4292)


   

(1s,3as,5ar,7r,8r,9ar,9br,11ar)-3a,5a,8-trihydroxy-9a,11a-dimethyl-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1-[(2r,3r)-2,3,6-trihydroxy-6-methylheptan-2-yl]-1h,2h,3h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-5-one

(1s,3as,5ar,7r,8r,9ar,9br,11ar)-3a,5a,8-trihydroxy-9a,11a-dimethyl-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1-[(2r,3r)-2,3,6-trihydroxy-6-methylheptan-2-yl]-1h,2h,3h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-5-one

C33H54O13 (658.3564)


   

3a,5a,8-trihydroxy-9a,11a-dimethyl-7-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1-(2,3,6-trihydroxy-6-methylheptan-2-yl)-1h,2h,3h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-5-one

3a,5a,8-trihydroxy-9a,11a-dimethyl-7-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1-(2,3,6-trihydroxy-6-methylheptan-2-yl)-1h,2h,3h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-5-one

C33H54O13 (658.3564)


   

(1r,1'r,2s,3'r,4'r,5r,5'r,6'r,10's,12's,13's,16'r,18's,21'r)-4',5,6',12',17',17'-hexamethyl-18'-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-3,6,9'-trioxaspiro[bicyclo[3.1.0]hexane-2,8'-hexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan]-14'-en-3'-yl acetate

(1r,1'r,2s,3'r,4'r,5r,5'r,6'r,10's,12's,13's,16'r,18's,21'r)-4',5,6',12',17',17'-hexamethyl-18'-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-3,6,9'-trioxaspiro[bicyclo[3.1.0]hexane-2,8'-hexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan]-14'-en-3'-yl acetate

C37H54O10 (658.3717)


   

1-(5-{2-[(3,4-dihydroxy-5-methoxyoxan-2-yl)oxy]ethyl}-6-methylheptan-2-yl)-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthrene-2,3,3b,5,6,7-hexol

1-(5-{2-[(3,4-dihydroxy-5-methoxyoxan-2-yl)oxy]ethyl}-6-methylheptan-2-yl)-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthrene-2,3,3b,5,6,7-hexol

C35H62O11 (658.4292)


   

[3,9-bis(acetyloxy)-8a-[(acetyloxy)methyl]-8-hydroxy-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-4-yl]methyl acetate

[3,9-bis(acetyloxy)-8a-[(acetyloxy)methyl]-8-hydroxy-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-4-yl]methyl acetate

C38H58O9 (658.4081)